Zydus announces Phase I trials of ZYIL1
NEW DELHI: Ahmedabad- based pharmaceutical company Zydus has announced that it has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. NLRP3 inflammasomes are involved in the inflammation process by production and release of pro-inflammatory cytokines IL-1β and IL-18. This harmful inflammation within the body […]